Jump to the main content block
  1. Home
  2. Division of Multi-Omics Informatics & Intelligence Computing

Jau-Song Yu

 

Jau-Song Yu

Appointment : Professor/Director of Molecular Medicine Research Center

Lab：Proteomics & Disease Biosignature Research Laboratory

Education : Ph.D.

University/Nation：National Tsing Hua University/Taiwan, Republic of Chin

Tel: 886-3-2118800 ext 5171

E-mail : yusong@mail.cgu.edu.tw

Research website : http://yusong1.wix.com/jsyu-lab

Research interests:

The research interests in my lab are to apply multi-omics approaches (genomics, transcriptomics, proteomics and metabolomics) to explore cancer biomarkers for early detection and to investigate novel cellular signaling networks in cell/cancer biology. Specific topics include: 

  1. Multiomic analysis of oral squamous cell carcinoma (OSCC). OSCC is a common cancer worldwide that represents a serious and growing problem in many parts of the globe, including Taiwan. However, little improvement has been made for the early detection and targeted therapy of OSCC in the past decades. Our lab leads the Molecular Medicine Research Center (MMRC) OSCC research team to participate in the International Cancer Proteogenome Consortium (ICPC), which is a part of international Cancer Moonshot program led by National Cancer Institute, USA. We apply the multi-omics approach to systemically analyze OSCC specimens (cancer tissues and adjacent non-tumor parts) using genomics (WES and Rseq), proteomics/phosphoproteomics, and metabolomics technology platform established in the MMRC, Chang Gung University. We hope to establish the first Taiwanese OSCC multi-omics blueprint which can greatly facilitate the discovery of new biology of OSCC, as well as the identification new biomarkers and/or therapeutic targets for early detection and effective treatment of OSCC.      

 

(2) R & D of clinically applicable cancer biomarkers. Cancer is one of the major death cause in the world, and delayed diagnosis of cancer represents the main reason of high mortality rate of many cancer types. We put efforts to discover cancer biomarkers from tissues, body fluids and cell lines and their verification in clinical specimens using proteomics technology platforms established in the Chang Gung University Proteomics Core Lab. We focus on four cancer types: OSCC, colorectal, pancreatic and liver cancers. Our long-term goal is to develop clinically useful biomarkers for early detection of cancer, which are expected to significantly improve human health (better patient outcome and less treatment cost). Currently, the major research outcomes for OSCC salivary biomarkers have been published in 2016/10 and 2020/8, respectively, from which a patent for OSCC detection method has been approved by several countries and transferred to a local biotech company for subsequent development of commercial assays (ELISA and rapid test). The product “Immuno-based Rapid Test for Detecting the Oral Cancer Biomarker-OCBM-1” derived from this Industry-university collaboration effort has been awarded the “2019 Taipei Biotech Awards – Technology Transfer Special Mention Award”. The OCBM-1 ELISA kit has obtained European CE marking (registration No. 00159706) on 2020/12, representing the first commercial ELISA kit invented from Taiwan for detecting oral cancer biomarker using saliva specimens. Additionally, the major research outcome for pancreatic cancer blood biomarker has been published in 2011/05, from which a patent for pancreatic cancer detection method has been approved by several countries and transferred to a local biotech company for subsequent development of commercial assays.

(3) Development of aptamer for medically important proteins. Aptamer is a kind of single chain RNA or DNA with unique 3D structure that can selectively bind to a specific target (proteins, peptides, carbohydrates, small molecules, toxins, and even live cells). Aptamer can be produced using an in vitro, PCR-based selection method called SELEX (systematic evolution of ligands by exponential enrichment), displaying high potential as a molecular tool for medically important targets. Our lab has established a high throughput SELEX platform for selecting DNA aptamers against different proteins. We focus on proteins with important clinical relevance or research utility, such as virus protein, snake venom protein, cancer biomarker, etc.

Publications: (*corresponding author)

最近五年所發表論文：*corresponding author

  1. Wu CC#, Lu YT#, Yeh TS#, Chan YH, Dash S, Yu JS* (2021) Fucosylated SERPINA1 is a novel serum marker for pancreatic cancer revealed by lectin affinity capture coupled with iTRAQ-based quantitative glycoproteomics approach. Int J Mol Sci 2021 Jun 4; 22(11), 6079. doi: 10.3390/ijms22116079. [PubMed]
  2. ● Liu JC, Chen YT, Hsieh YJ, Wu CC, Huang MC, Hsu YC, Wu CT, Chen CK, Dash S, Yu JS* (2021) Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses. Scientific Reports 2021 May 5;11(1):9583. doi: 10.1038/s41598-021-89089-4. [PubMed]
  3. Chiang SF+, Huang HH+, Tsai WS+, Tan BCM, Yang CY, Huang PJ, Chang IYF, Lin J, Lu PS, Chin E, Liu YH, Yu JS, Chiang JM, Hung HY, You JF, Liu H*. (2021) Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Biomedical Journal Available online 16 March 2021. doi: 10.1016/j.bj.2021.03.001
  4. Wu CP*, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV (2021) Overexpression of human ABCB1 and ABCG2 reduces the susceptibility of cancer cells to the histone deacetylase 6-specific inhibitor citarinostat. Int J Mol Sci 2021 Mar 5; 22(5), 2592. doi: 10.3390/ijms22052592. [PubMed]
  5. Liu CC#, Yang YH#, Hsiao YC, Wang PJ, Liu JC, Liu CH, Hsieh WC, Lin CC, Yu JS* (2021) Rapid and efficient enrichment of snake venoms from human plasma by a strong cation exchange tip column to improve snakebite diagnosis. Toxins 2021 Feb 13; 13(2), 140. doi: 10.3390/toxins13020140. [PubMed]
  6. ●● Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IYF, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS*. (2020) Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. Cancers (Basel). 2020 Aug 13; 12(8):E2273. doi: 10.3390/cancers12082273. [PubMed]
  7. Chen YT#, Chang IYF#, Kan CH, Liu YH, Kuo YP, Tseng HH, Chen HC, Liu H, Chang YS, Yu JS, Chang KP, Tan BCM*. circRNAome profiling unveils a novel oncogenic circFLNB circuit in oral cancer. (2020) Cells. 2020 Aug 10; 9(8):E1868. doi: 10.3390/cells9081868 [PubMed]
  8. ● Lin YH*, Wu CC, Su WT, Tseng PC, Hsueh YY, Hsiao YC, Chang KP, Yu JS*, Chuang YR. (2020) Target peptide enrichment microfluidic chip for rapid detection of oral squamous cell carcinoma using stable isotope standards and capture by anti-peptide antibodies. Sensors and Actuators B: Chemical 2020 Nov 1, 322:128607
  9. Wu CP*, Hung CY, Lusvarghi S, Huang YH, Tseng PJ, Hung TH, Yu JS, Ambudkar SV. (2020) Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology 2020 Jul 4:114137. doi: 10.1016/j.bcp.2020.114137. [PubMed]
  10. Hsueh PC, Wu KA, Yang CY, Hsu CW, Wang CL, Hung CM, Chen YT, Yu JS, Wu CC* (2020) Metabolomic profiling of parapneumonic effusion reveals a regulatory role of dipeptides in interleukin-8 production in neutrophil-like cells. Analytica Chimica Acta 2020 Sep 1;1128:238-250. doi: 10.1016/j.aca.2020.06.022. [PubMed]
  11. Chakraborty A, Lin WC, Lin YT, Huang KJ, Wang PY, Chang YF, Wang HI, Ma KT, Wang CY, Huang XR, Lee YH, Chen BC, Hsieh YJ, Chien KY, Lin TY, Liu JL, Sung LY, Yu JS, Chang YS, Pai LM*. (2020) SNAP29 mediates the assembly of histidine-induced CTP synthase filaments in proximity to the cytokeratin network. J Cell Sci 2020 May 11;133(9):jcs240200. doi: 10.1242/jcs.240200. [PubMed]
  12. Hsiao TF#, Wang CL#, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ*. (2020) Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clin Cancer Res. 2020 Jul 1;26(13):3220-3229. doi: 10.1158/1078-0432.CCR-19-3972. [PubMed]
  13. Liu CC#, Chou YS#, Chen CY, Liu KL, Huang GJ, Yu JS, Wu CJ, Liaw GW, Hsieh CH*, Chen CK*. (2020) Pathogenesis of local necrosis induced by Naja atra venom: Assessment of the neutralization ability of Taiwanese freeze-dried neurotoxic antivenom in animal models. PLOS Neglected Tropical Diseases. 2020 Feb 7;14(2): e0008054. doi: 10.1371/journal.pntd.0008054. [PubMed]
  14. ●● Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS* (2020) An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. Anal Chim Acta 1100:118-130. doi: 10.1016/j.aca.2019.12.006. [PubMed]
  15. ● Chi LM#, Hsiao YC#, Chien KY#, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IYF, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP*, Yu JS*. (2020) Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J Proteomics. 2020 Jan 16; 211:103571. doi: 10.1016/j.jprot.2019.103571. [PubMed]
  16. Lin WR*, Chiang JM, Lim SN, Su MY, Chen TH, Huang SW, Chen CW, Wu RC, Tsai CL, Lin YH, Alison MR, Hsieh SY, Yu JS, Chiu CT, Yeh CT. (2019) Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas. EBioMedicine. 2019 Jun;44:334-345. doi: 10.1016/j.ebiom.2019.05.031. [PubMed]
  17. Yu J-S. (2019) From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science. Biomedical Journal 2019 Apr; 42(2), 80-83 doi: 10.1016/j.bj.2019.03.004. (Invited article) [PubMed]
  18. Chen Y-T*, Tsai C-H, Chen C-L, Yu J-S, Chang Y-H*. (2019) Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. J. Food Drug Anal. 2019 Apr; 27(2):387-403. doi: 10.1016/j.jfda.2018.09.005. [PubMed]
  19. Chen Y-T*, Huang H-C, Hsieh Y-J, Fu S-H, Li L, Chen C-L, Chu L-J, Yu J-S. (2019) Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. J. Food Drug Anal. 2019 Apr; 27(2): 460-474. doi: 10.1016/ j.jfda.2018.11.008. [PubMed]
  20. Chou PH, Liao WC; Tsai KW, Chen KC Yu JS, Chen TW*. (2019) TACCO, a database connecting transcriptome alterations, pathway alterations and clinical outcomes in cancers. Scientific Reports 2019 Mar 7;9(1):3877. doi: 10.1038/s41598-019-40629-z. [PubMed]
  21. Wang P#, Geng J#, Gao J, Zhao H, Li J, Shi Y, Yang B, Xiao C, Linghu Y, Sun X, Chen X, Hong L, Qin F, Li X, Yu JS, You H, Yuan Z, Zhou D, Johnson RL, Chen L* (2019) Macrophage achieves self-protection against oxidative stress-induced ageing through Mst-Nrf2 axis. Nature Communications 2019 Feb 14;10(1):755. doi: 10.1038/s41467-019-08680-6. [PubMed]
  22. Hsu C-W#, Chen Y-T#, Hsieh Y-J, Chang K-P, Hsueh P-C, Yu J-S, Chang Y-S, Li L*, Wu C-C* (2019) Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma. Anal Chim Acta 2019 Mar 7;1050:113-122. doi: 10.1016/j.aca.2018.10.070. [PubMed]
  23. Lin Y-H*, Chang H-Y, Wu C-C, Wu C-W, Chang K-P, Yu J-S*. (2019). BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. Anal. Bioanal. Chem. 2019 Feb;411(5):1085-1094. doi: 10.1007/s00216-018-1536-2. [PubMed]
  24. Lee C-C#, Hsieh Y-J#, Chen S-W, Fu S-H, Hsu C-W, Wu C-C, Han W, Li Y, Tao H, Chang Y-S, Yu J-S, Li L*, Chang C-H*, Chen Y-T*. (2018) Bretschneider solution-induced alterations in the urine metabolome in cardiac surgery patients. Scientific Reports 2018 Dec 11;8(1):17774. [PubMed]
  25. ●● Liu C-C#, Yu J-S#, Wang P-J, Hsiao Y-C, Liu C-H, Chen Y-C, Lai P-F, Hsu C-P, Fann W-C, Lin C-C*. (2018) Development of sandwich ELISA and lateral flow strip assays for diagnosing clinically significant snakebite in Taiwan. PLOS Neglected Tropical Diseases. 2018 Dec 3;12(12):e0007014. [PubMed] #Contributed equally
  26. Lin W-C, Chakraborty A, Huang S-C, Wang P-Y, Hsieh Y-J, Chien K-Y, Lee Y-H, Chang C-C, Tang H-Y, Lin Y-T, Tung C-S, Luo J-D, Chen T-W, Lin T-Y, Cheng M-L, Chen Y-T, Yeh C-T; Liu J-L, Sung L-Y, Shiao M-S, Yu J-S, Chang Y-S, Pai L-M*. (2018) Histidine-dependent protein methylation is required for compartmentalization of CTP synthase. Cell Reports 2018 Sep 4;24(10):2733-2745.e7. [PubMed]
  27. Wu CP*, Hsieh YJ, Murakami M, Vahedi S, Hsiao SH, Yeh N, Chou AW, Li YQ, Wu YS, Yu JS, Ambudkar SV. (2018) Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochem Pharmacol. 2018 Jul 17. 155:316-325. [PubMed]
  28. Liu C-C#, Lin C-C#, Hsiao Y-C, Wang P-J, Yu J-S*. (2018) Proteomic characterization of six Taiwanese snake venoms: Identification of species-specific proteins and development of a SISCAPA-MRM assay for cobra venom factors. J. Proteomics 2018 Sep 15, 187:59-68. [PubMed]
  29. Huang Y-H, Lin K-H, Yu J-S, Wu T-J, Lee W-C, Chao C-K, Pan T-L, Yeh C-T*. (2018) Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol. Carcinog. 2018 Apr 19. 57:1087–1101. [PubMed]
  30. Chen C-T, Liu C-C, Yu J-S, Li H-H, Lai M-C*. (2018) Integrated omics profiling identifies hypoxia-regulated genes in HCT116 colon cancer cells J. Proteomics 188:139-151. [PubMed]
  31. ● Chu LJ#, Hsiao YC#, Chiang WF#, Tsai CJ, Lin SY, Chang KP, Chien CY, Yu JS*. (2018) Use of saliva protein biomarkers for diagnosis of oral cavity cancer. International Journal of Head and Neck Science June 2018; 2(2): 56-68. (Invited review article) [Link]
  32. Tsai C-H,#, Chen Y-T*,#, Chang Y-H#, Hsueh C, Liu C-Y, Chang Y-S, Chen C-L*, Yu J-S* (2018) Systematic verification of bladder cancer-associated tissue protein biomarker candidates in urine specimens. Oncotraget 2018 Jul 20;9(56):30731-30747. [PubMed]
  33. Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, and Tan BC*. (2018) MiR-31-5p-ACOX1 axis enhances tumorigenic fitness in oral squamous cell carcinoma via the promigratory prostaglandin E2. Theranostics 2018 Jan 1;8(2):486-504. [PubMed]
  34. ●● Hsiao YC#, Chu LJ#, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, and Yu JS*. (2018) Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry. (2018) Proteomics-Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700039. [PubMed]
  35. Wu CC#, Lin JD#, Chen JT, Chang CM, Weng HF, Hsueh C, Chien HP and Yu JS*. (2018) Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery. Oncotarget 9:12079-12100. [PubMed]
  36. Liu CC, You CH, Yu JS*, Huang GJ, Liu CH, Wang PJ, and Lin CC*. (2017) Analysis of the efficacy of Taiwanese freeze neurotoxic antivenom against Southeast Asian cobra venoms through proteomics and animal model approaches. PLOS Neglected Tropical Disease. 2017 Dec 15;11(12): e0006138. [PubMed]
  37. ●● Hsiao Y-C, Chi L-M, Chien K-Y, Chiang W-F, Chen S-F, Chuang Y-N, Lin S-Y, Wu C-C, Chu LJ, Chen Y-T, Chia S-L, Chien C-Y, Chang K-P, Chang Y-S, and Yu J-S*. (2017) Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. Mol. Cell. Proteomics 2017 Oct;16(10):1829-1849. [PubMed]
  38. ●● Chen TW#, Lee CC#, Liu H#, Wu CS#, Pickering CR#, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP*, Chang YS*. (2017) APOBEC3A is an oral cancer prognostic biomarker in carriers of an APOBEC deletion polymorphism. Nature Communications. 2017 Sep 6;8(1):465. [PubMed]
  39. ● Hsiao YC#, Chu LJ#, Chen JT, Yeh TS and Yu JS*. (2017) Proteomic profiling of the cancer cell secretome: informing clinical research. Expert Review of Proteomics (Invited review article) 2017 Sep;14(9):737-756. [PubMed]
  40. ●● Peng Y#, Zhang M#, Zheng L#, Liang Q#, Li H#, Chen J-T, Guo H, Yoshina S, Chen Y-Z, Zhao X, Wu X, Liu B, Mitani S, Yu J-S, Ding Xue*. (2017) Cysteine protease cathepsin B mediates radiation-induced bystander effects. Nature 547(7664), 458–462 (27 July 2017) [PubMed]
  41. Cheng JC*, Tseng CP, Liao MH, Peng CY, Yu JS, Chuang PH, Huang JT, Chen JJW. (2017) Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. Scientific Reports. 2017 June 30;7:4448. doi:10.1038/s41598-017-04259-7 [PubMed]
  42. ● Hsieh Y-J#, Chien K-Y#, Yang I-F, Lee I-N, Wu C-C, Huang T-Y, and Yu J-S* (2017) Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. Scientific Reports 2017 May 2;7(1):1370. doi: 10.1038/s41598-017-01409-9. [PubMed]
  43. Shao CH, Chen CL, Lin JY, Chen CJ, Fu SH, Chen YT, Chang YS, Yu JS, Tsui KH, Juo CG*, Wu KP*. (2017) Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics. Oncotarget. 2017 Mar 21. 2017; 8:38802-38810 doi: 10.18632/oncotarget.16393. [PubMed]
  44. Chen Y-T*, Chen H-W, Wu C-F, Chu L-J, Chiang W-F, Wu C-C, Yu J-S, Tsai C-H, Liang K-H, Chang Y-S, Wu M, Ou Yang W-T. (2017) Development of a multiplexed LC-MRM/MS method for evaluation of salivary proteins as oral cancer biomarkers. Mol. Cell. Proteomics 2017 May;16(5):799-811. [PubMed]
  45. ● Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Yeh CT*, Yu JS*. (2017) Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J. Proteomics. 2017 Mar 22;157:40-51. [PubMed]
  46. Chung I-C, OuYang C-N, Yuan S-N, Li H-P, Chen J-T, Shieh H-R, Chen Y-J, Ojcius DM, Yu J-S, Chang Y-S, Chen L-C*. (2016) Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. Scientific Reports 2016 Oct 31; 6:36214. [PubMed]
  47. ●● Yu JS#, Chen YT#, Chiang WF#, Hsiao YC#, Chu LJ#, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS*, Hartwell LH* (2016) Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan. Proc Natl Acad Sci USA. 2016 Oct 11;113(41):11549-11554. (#Co-first authors) [PubMed]
  48. Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS, Yu CJ.* (2016) Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol. Cell. Proteomics 2016 Jul;15(7):2396-410. [PubMed]
  49. ● Chen H#, Hsiao Y-C#, Chiang S-F, Wu C-C, Lin Y-T, Liu H, Zhao H, Chen J-S, Chang Y-S, and Yu J-S*. (2016) Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. Anal. Chim. Acta 2016 Aug 24; 933:144-55. [PubMed]
  50. Wang C-I, Chan Y-Y, Wang C-L, Yu J-S, Chang Y-S, and Yu C-J*. (2016) mTOR regulates proteasomal degradation and Dp1/E2F1-mediated transcription of KPNA2 in lung cancer cells. Oncotarget 2016 May 3;7(18):25432-42. [PubMed]
  51. Wu C-P*, Hsieh Y-J, Hsiao S-H, Su C-Y, Li Y-Q, Huang Y-H, Huang C-W, Hsieh C-H, Yu J-S and Wu Y-S*. (2016) Human ATP-Binding Cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase. Mol. Pharm. 2016 Mar 7;13(3):784-94. [PubMed]

Patents:

  1. Jau-Song Yu, Kai-Ping Chang. (2012) Method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker. United States Patent, US8,148,059B2, Apr. 3, 2012. Patent period 2012/4/3~2029/10/30
  2. Yi-Ting Chen, Jau-Song Yu, Chien-Lun Chen, Yu-Sun Chang (2013) Bladder cancer biomarker and test method using the same. R.O.C. Patent I390204, 2013/03/21-2030/2/10
  3. Jau-Song Yu, Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Yu-Sun Chang (2013) A method for detecting pancreatic cancer using the serological marker ULBP2. R.O.C. Patent I408370, 2013/9/11~2031/5/18
  4. Jau-Song Yu, Ming-Hung Tsai, Ling-Ling Hsieh (2014) Plasma Marker for Distal Metastasis in Colorectal Cancer. R.O.C. Patent I444386, 2014/7/11~2032/4/9
  5. Chao-Sung Lai, Jau-Song Yu, Yu-Sun Chang, Po-Lung Yang, Tseng-Fu Lu, Yi-Ting Lin, Wen-Yu Chuang, Ting-Chun Yu, I-Shun Wang, Jyh-Ping Chen, Chou Chien (2014) Surface treatment method by using the NH3 plasma treatment to modify the sensing thin-film. United States Patent, US8741679 B2, June 3, 2014. Patent period 2014/6/3~2032/5/8
  6. Jau-Song Yu, Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Yu-Sun Chang (2014) A method for detecting pancreatic cancer using the serological marker ULBP2. European patent, EP2525227B1, Patent period: 2/16/2015~5/16/2032 (Poland), 11/19/2014~  5/16/2032 (France), 12/11/2014~5/16/2032 (Germany), 1/20/2015~5/16/2032 (Italy), 11/19/2014~5/16/2032 (United Kingdom), 1/13/2015~5/16/2032 (Spain)
  7. Yi-Ting Chen, Jau-Song Yu, Chien-Lun Chen, Yu-Sun Chang (2016) Urinary biomarkers for predicting bladder and kidney cancers. R.O.C. Patent I522367, 2016/2/21~2033/4/11
  8. Jau-Song Yu, Wei-Fan Chiang, Yi-Ting Chen, Yu-Sun Chang, Lai-Chu See, Yung Chin Hsiao, Kai-Ping Chang. (2016) Apparatus and methods for detecting oral squamous cell carcinoma. US provisional application. No. 62309766 (application date: 2016/03/17)
  9. Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2017) Methods for cancer diagnosis and prognosis. International application (PCT) No. PCT/US17/22853 (application date: 2017/03/17)
  10. Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Yu-Sun Chang, Lai-Chu See, Kai-Ping Chang. (2019) Methods for cancer diagnosis and prognosis. R.O.C. Patent I651536, 2019/2/21~2037/3/15 (application No. 106108654, application date: 2017/03/17)
  11. Err-Cheng Chan, Kuei-Tien Chen, Jau-Song Yu, Yu-Sun Chang Jinn-Shiun Chen. (2017) Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells. United States Patent, US 9,835,636 B2, Dec. 5, 2017. Patent period: 2011/10/4-2031/10/3
  12. Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2020) Methods for cancer diagnosis and prognosis. European patent, EP3430406B1, Patent period: 2020/12/02~2037/3/17. (application date: 2017/03/17; application No. 17767588.1)
  13. Ya-Ting Chang, Jau-Song Yu, Jun-Sheng Wang, Shu-Fang Wu, Chih-Jou Chen, Yen-Chun Liu (2021) Matrix metalloproteinase-1 monoclonal antibody, detection kit and detection method thereof. R.O.C. Patent (application No. 109106582, application date 2020/02/27, approval date 2021/05/14)

Technology transfer & Industry-university collaboration:

1. The technology entitled “Method for cancer diagnosis and prognosis” has been transferred to See & Treatment LTD., time period: 2017/1/23-2023/1/22. Industry-university collaboration project entitled “Development of immunoassay kits for detecting oral cancer biomarkers”, time period: 2017/6/1-2019/5/31.

2. The technology entitled “Serum biomarker for pancreatic cancer and its application” has been transferred to See & Treatment LTD., time period: 2020/01/10~2030/01/10. Industry-university collaboration project entitled “Development of immunoassay kits for detecting pancreatic cancer biomarkers”, time period: 2020/9/1-2022/8/31.

 

 

 

Click Num:
Print